SIKANDER AILAWADHI MD NPI 1063670339

NPI Information

  • NPI: 1063670339
  • Provider Name: SIKANDER AILAWADHI, MD
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 4500 SAN PABLO RD S
    JACKSONVILLE, FL
    ZIP 32224
  • Phone: (904) 953-2000

Map and Directions

Get Directions

NPI Details

Sikander Ailawadhi, MD is a hematology and oncology internal medicine in Jacksonville, FL with 26 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Sikander Ailawadhi, MD NPI is 1063670339. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4500 SAN PABLO RD S
JACKSONVILLE, FL
ZIP 32224-865
Phone: (904) 953-2000

The NPI 1063670339 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, fosaprepitant, 1 mg (HCPCS:J1453)
  • Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
  • Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
  • Injection, nivolumab, 1 mg (HCPCS:J9299)
  • Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
  • Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
  • Injection, paclitaxel, 1 mg (HCPCS:J9267)
  • Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
  • Injection, docetaxel, 1 mg (HCPCS:J9171)
  • Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
  • Injection, durvalumab, 10 mg (HCPCS:J9173)
  • Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
  • Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
  • Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
  • Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
  • Injection, fulvestrant, 25 mg (HCPCS:J9395)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Injection, fluorouracil, 500 mg (HCPCS:J9190)
  • Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
  • Injection, carboplatin, 50 mg (HCPCS:J9045)
  • Collection of blood sample from implanted device (HCPCS:36591)
  • Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
  • Cyclophosphamide, 100 mg (HCPCS:J9070)
  • Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
  • Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Injection, potassium chloride, per 2 meq (HCPCS:J3480)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Injection, zoledronic acid, 1 mg (HCPCS:J3489)
  • Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
  • Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
  • Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
  • Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
  • Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
  • Injection of drug or substance into vein (HCPCS:96374)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Hospital discharge day management, more than 30 minutes (HCPCS:99239)
  • Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
  • Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)

The enumeration date for this NPI number is 5/23/2008 and was last updated on 8/31/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RH0003XInternal MedicineHematology & OncologyME118080FLORIDAYes

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.